

**Press Release**

Friday, November 11, 2011

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR CARBOPLATIN INJECTION

- **Sixth US FDA Approval For Oncology**

---

**November 11, 2011, Bangalore:** Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for ***Carboplatin Injection 10 mg/ mL packaged in 50 mg/ 5 mL, 150 mg/ 15 mL, 450 mg/ 45 mL and 600 mg/ 60 mL Multi-dose vials.***

According to IMS data June'11, the US market for generic Carboplatin is approximately USD 35 Million.


Carboplatin is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

### **About Carboplatin**

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents, and in secondary treatment of advanced ovarian carcinoma which has recurred after prior chemotherapy.

### **About Agila Specialties**

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world.



Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.

**About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

<b><u>Strides</u></b>	<b><u>PR Consultancy</u></b>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice   Weber Shandwick Mahesh Nair, +91 9880376648 <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>
Mr. Ajay Singh : +91 80 6784 0813	
Mr. Kannan N : +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 <a href="mailto:hiba@corvoshandwick.co.in">hiba@corvoshandwick.co.in</a>

